NOVOZYMES A/S/S (OTCMKTS:NVZMY) and Coherus Biosciences (NASDAQ:CHRS) are both basic materials companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.
NOVOZYMES A/S/S pays an annual dividend of $0.49 per share and has a dividend yield of 1.1%. Coherus Biosciences does not pay a dividend. NOVOZYMES A/S/S pays out 28.0% of its earnings in the form of a dividend.
Earnings and Valuation
This table compares NOVOZYMES A/S/S and Coherus Biosciences’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|NOVOZYMES A/S/S||$2.28 billion||6.01||$511.29 million||$1.75||26.39|
|Coherus Biosciences||$1.56 million||632.33||-$238.17 million||($4.48)||-3.24|
NOVOZYMES A/S/S has higher revenue and earnings than Coherus Biosciences. Coherus Biosciences is trading at a lower price-to-earnings ratio than NOVOZYMES A/S/S, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
0.2% of NOVOZYMES A/S/S shares are owned by institutional investors. Comparatively, 96.7% of Coherus Biosciences shares are owned by institutional investors. 19.6% of Coherus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and target prices for NOVOZYMES A/S/S and Coherus Biosciences, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Coherus Biosciences has a consensus price target of $30.75, indicating a potential upside of 112.07%. Given Coherus Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Coherus Biosciences is more favorable than NOVOZYMES A/S/S.
Volatility & Risk
NOVOZYMES A/S/S has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Coherus Biosciences has a beta of 3.66, indicating that its stock price is 266% more volatile than the S&P 500.
This table compares NOVOZYMES A/S/S and Coherus Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
About NOVOZYMES A/S/S
Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. It operates in three divisions: Household Care & Technical, Agriculture & Bioenergy, and Food & Beverages. The company offers enzymes for use in household care products, such as laundry detergents, hand and automatic dishwashing soaps, and professional cleaning products. It also provides enzymes for baking applications, including freshness, product appearance, dough improvement, etc.; and brewing applications comprising fermentation control, separation and filtration, etc., as well as for use in lactose-free dairy, trans fats removal, etc. in the food and beverages industry. In addition, the company offers enzymes and microorganisms for use in the production of cellulosic ethanol, starch-based ethanol, enzymatic biodiesel, and sugarcane ethanol in the bioenergy industry; and feed enzymes for use in animal feed, probiotics for animal health applications, microbials for aquaculture applications, and other enzymes and microorganisms for plant health and crop yield applications in the agriculture and feed industry. Further, it provides enzymes and microorganisms for use in textile processing, pulp and paper production, leather preparation, pharmaceuticals, and wastewater treatment solutions. The company has a strategic collaboration with Boehringer Ingelheim Animal Health for research and development, production, marketing, and sale of a portfolio of probiotic products. It also has a collaboration agreement with Elanco Animal Health Incorporated. Novozymes A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
About Coherus Biosciences
Coherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis. It is also developing a pipeline of products in therapeutic areas, such as oncology, immunology, and ophthalmology comprising CHS-3351, a ranibizumab biosimilar; and CHS-2020, an aflibercept biosimilar, as well as CHS-131, a small molecule for multiple sclerosis. Coherus BioSciences, Inc. has license agreement with Selexis SA and Genentech, Inc. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Receive News & Ratings for NOVOZYMES A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NOVOZYMES A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.